Drugs / HBOC-201
HBOC-201
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT00479895 | Apr 2007 → Mar 2008 | acute coronary syndrome, arterial occlusion | Biopure Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00300040 | May 2006 → Jun 2008 | peripheral vascular disease | Biopure Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00301535 | Feb 2006 → Jul 2008 | coronary artery disorder | Biopure Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT00317512 | Dec 2003 → Apr 2005 | intermediate coronary syndrome, myocardial infarction | Biopure Corporation | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01881503 | Oct 2013 → Oct 2026 expected | anemia | Englewood Hospital and Medical Center | Enrolling by invitation | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT03633604 | — | anemia | Michael Boisen | No longer available | No outcome recorded |
| — | NCT02684474 | — | anemia | Johns Hopkins University | No longer available | No outcome recorded |
| — | NCT02934282 | — | anemia | Mauricio Lynn | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2019-06-03 | HbO2 Therapeutics LLC | Results Hemoglobin Oxygen Therapeutics LLC Announces Multiple Presentations Using Hemopure® in Donor Livers hbo2therapeutics.com ↗
Preliminary results demonstrate that machine perfusion technology using Hemopure, a novel synthetic oxygen carrying solution, safely increases the number of transplantable livers and with the added benefit of avoiding the need for human blood products, |
| 2019-04-18 | HbO2 Therapeutics LLC | Results Hemopure Plays A Pivotal Role In A Pioneering Study Published in Nature hbo2therapeutics.com ↗
during a six-hour perfusion period, the researchers observed a reduction in cell death and evidence for the restoration of some cellular functions, including spontaneous synaptic activity. |
| 2019-04-09 | HbO2 Therapeutics LLC | Results Preclinical Results on Hemopure in Kidneys Discarded for Human Transplantation hbo2therapeutics.com ↗
The results showed that Hemopure performed comparably to packed red blood cells while overcoming logistical and clinical issues associated with red blood cell-based solutions including longer shelf half-lives, ease of use and accessibility, and negligible infectious risks. |
| 2019-02-13 | HbO2 Therapeutics LLC | Results Updated Results From The Netherlands Leading Liver Transplant Hospital hbo2therapeutics.com ↗
To date, results show 100 % transplant and survival rates for all patients. |
All press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBOC-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02934282 ↗ |
| Known as | Hemoglobin Based Oxygen Carrier-201 | “Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)” NCT00479895 ↗1“Drug: Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)” NCT00317512 ↗ |
| Known as | hemoglobin glutamer-250 bovine | “HBOC-201 (hemoglobin glutamer-250 bovine)” NCT00301535 ↗ |
| Known as | Hemopure | “Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)” NCT00479895 ↗1“Hemopure® (HBOC-201)” NCT00301535 ↗ |
| Modality | Protein / enzyme biologic | “purified, glutaraldehyde-polymerized bovine hemoglobin” NCT00301535 ↗ |
| Route | Intravenous | “intravenous” NCT00300040 ↗ |